Buying Iranian Pharmaceutical Products for India’s Healthcare Market

The pharmaceutical industry of India is one of the world's fastest-growing, with a population of more than 1.4 billion and a persistent need for low-cost medicines. Increasing expenditure in health care, and rising occurrences of non-communicable disorders like diabetes, cancer, and cardiovascular diseases, has put a huge responsibility upon government and private health care units to provide treatment at subsidized rates. Against such a backdrop, the option of buying medicines from new cost-effective sources has seemed more appealing than ever.
One of those nations here is Iran. Famous for having a very prosperous pharmaceutical sector, Iran manufactures nearly everything of its own local pharmaceutical needs and exports extra medicines to over 50 nations around the globe. These are not just generic medicines either; Iran has come out a surprising player in the biotechnology, biosimilars, and specialty medicines area too. Iranian pharmaceutical exports to India can provide a gateway to cheap but quality medicines to the pharma firms of India.

Market Overview

Iran's pharma industry is among the biggest in the Middle East and boasts more than 340 factories manufacturing a gigantic quantity of medicines. Even more than 99% of Iran's indigenous drug requirements are fulfilled locally with only a negligible fraction fulfilled from abroad for extremely specialized medical procedures. This level of high self-sufficiency has left Iran with surplus capacity to export. Finished pharmaceuticals, APIs, and raw materials are exported by a cumulative total of approximately 100 Iranian companies to dozens of nations across Asia, Africa, and Eastern Europe.
Another major factor is demand. India's pharmaceutical demand is increasing tremendously with an expanding middle class and health initiatives such as Ayushman Bharat from the government. To address the demand, affordable medicines are required. 
India’s pharmaceutical imports by country (2018, INR million):

Industry Profile and Export Capacity

Iran's pharmaceutical industry is subsidized but has independent firms and innovation capability. Biotechnology expenditure has built an emerging biosimilars industry. Iran, the Global Biosimilars Initiative says, has licensed many "copied" biopharmaceuticals (biosimilars) for cancer and autoimmune disorders. Iran, for instance, makes biosimilars of blockbuster medicines such as bevacizumab (Arvestin), etanercept (Altebrel), and interferon beta (ReciGen). It is a show of technological competence and a diversified product mix of more than just generics.

Price and Quality Advantages

Economics is one important area of appeal. Iranian suppliers emphasize low cost of production (i.e. cheap labor and locally available API) and government pricing policy ensuring cheap medicines. Official statements attest Iranian medicines are substantially less expensive than European levels and of better quality. Iranian generics are reported to compare equally to Indian generics by various companies. Bargain pricing is to India’s importers’ advantage: a drug which would cost Rs. X from Europe would cost substantially less from Iran even including shipping, due to Iran’s rates for export.

Key Pharmaceutical Products

Iran is a source of generic and advanced biopharmaceuticals too. Iran has innovative biosimilars, niche drugs, and generic essential medicines in its pipeline. Indian companies are more interested in the following categories:
•    Generic Medicines: These include everyday treatments such as antibiotics, pain relievers, cardiovascular drugs, and diabetic medicines. Iranian generics are widely recognized for being affordable and effective, falling under the category of generic drugs Iran specializes in.
•    Active Pharmaceutical Ingredients (APIs): Iran produces certain APIs and intermediates, making them an alternative source for Indian manufacturers.
•    Biopharmaceuticals and Biosimilars: Iran has developed several biosimilars for cancer, autoimmune diseases, and multiple sclerosis. These include products like Arvestin (bevacizumab biosimilar) and Altebrel (etanercept biosimilar).
•    Over-the-Counter (OTC) and Nutritional Products: Vitamins, dietary supplements, and herbal medicines are also a growing segment of Iranian exports.

Selected Iranian Biopharmaceutical Products (Biosimilars):

       
Generic Drugs from Iran

Bulk generic medicines are the backbone of Iran's pharmaceutical industry. Paracetamol, ibuprofen, amoxicillin, metformin, and statin are produced in bulk. They cost less and are therefore highly in demand with bulk buyers in India. To take one example, a generic Iranian antibiotic costs 30–40% less if imported from Iran than if one is imported from Europe with no compromise in world quality standards.

Specialized Medical Products

Apart from generics, Iran is equally dominant in specialty areas like biotechnology and oncology. Of particular interest are the biosimilars, wherein Iranian firms make copies of high-cost biologic medicines. Iran has a proud tradition of herbal medicine, and some of the firms blend classical pharmaceutical practice with ancient wisdom to create herbal-based medicines. These medicines could well enjoy a niche in India, too, where Ayurveda and herbal medicine are equally popular.

Trade Regulations and Requirements

Import into India of pharmaceuticals is regulated under strict control. Imported pharmaceuticals will be required to comply with the terms of the Drugs and Cosmetics Act (1940) and Rules (1945). Approvals are regulated by the Drug Controller General of India (DCGI) and the Central Drugs Standard Control Organization (CDSCO). It is required of an Iranian manufacturer to register with CDSCO whenever possible, and the aforementioned product must already be listed in the register of India or enter India under a valid license. Practically speaking, the importer from India (licensed with an import-export permit) needs a DCGI-warranted Import License (Form 10) and, in most cases, a Registration Certificate (Form 41) for each drug. The importer should also compel the Iranian supplier to comply with Indian quality specifications; non-Indian producers are required to cooperate with DCGI inspections and provide undertakings when required, according to Nishith Desai.

Import Licensing and Compliance

In order to introduce Iranian medicines into India, Indian companies are required to submit to CDSCO drug safety, effectiveness, and GMP-compliance dossiers. Foreign companies are required to be “Notified Drugs” under DCGI and the foreign product is required to be of Indian pharmacopoeia standard and its equivalents. India has recently started inspection of plants outside India; Indian inspectors are capable of auditing the outside plant prior to product registration. Importers are required to abide by the National Informatics Centre (NIC) and Indian Customs–i.e., use of FDA import portal and clearance from authorized ports. All labeling has to be in English (and local language in case of necessity) and has to include mandated information under law in India.

Trade Agreements and Tariffs

India and Iran are negotiating a preferential trade agreement (PTA) to facilitate commerce and reduce duties. Should a PTA be accomplished, some pharmaceuticals could be given lower duties and become more affordable. Finished pharmaceuticals and APIs into India currently can be charged import duties (10% + more based on the category) and GST, while Iran can levy low or no export duties on medicines. Indian importers must verify the Harmonized System (HS) code and paid duties on each commodity. Both nations having had previous oil-for-goods settlements, pharmaceuticals had been traded under concessional rates at times. Indian banks like UCO Bank had a special Rupee payment facility for Iranian trade, settling accounts on medicines and edibles. This means Iranian imports can be paid in rupees, avoiding some restrictions on currency.
Sanctions compliance is also a worry: though India avails exemptions for Iran trade of medicines and foodstuffs, it is important that the shipments do not become victims of global sanctions. Payment by Indian importers is typically avoided in dollars and is made in the approved Rupee Vostro accounts or barter deals (some of the Iranian petroleum payments have been made in medical equipment). Iran's Trade Promotion Organization has had positive orientations towards trade through new banking connections and private banking channels in India.

Logistics and Payment Solutions

Getting a secure supply chain from Iran needs planning of shipping and payment. India and Iran are divided by the Arabian Sea but share well-known routes. Sea freight from port of Bandar Abbas (IRAN) arrives at the Indian ports of Mumbai or Kandla with a shipping of around 7–10 days by sea. Fast, costliest shipments (such as biotech pharmaceuticals) are usually air-freighted with the Iranian airports such as Tehran or Shiraz to major airports of India such as Delhi and Mumbai with a shipping of 2–3 days. Sea freight is cost-effective for bulk shipments and air freight is okay for delicate shipments. Iranian logistics will sometimes provide an option of refrigeration containers for pharmaceuticals. Freight cost and shipping time may be optimized and minimizing the other parameter by taking advantage of specialty pharma carriers and by warehousing products in bonded warehouses when the situation calls for it. Dual-shipping arrangements (sea-air combinations) may optimize cost vs. speed for the medium-sized shipments.

Shipping and Distribution Channels

The majority of Iranian pharmaceutical exports are routed through Bandar Abbas port, well-linked to Indian ports such as Mumbai, Mundra, and Kandla. Sea shipment is 7–10 days. Flights from Tehran to New Delhi or Mumbai are 2–3 days for delicate or high-cost pharmaceuticals such as vaccines and biosimilars. Cold chain facilities — refrigerated containers and temperature-controlled warehouses — are in place to guarantee drug stability. Indian investment in Iranian port of Chabahar increases connectivity even further. Although planned initially to serve Afghanistan and central Asia, it could also promote direct India–Iran pharmaceutical trade.

Secure Payment Options and Currency Exchange

One of the Iran pharma trade barriers is the existence of world sanctions, which do not permit U.S. dollar settlements. India is taking advantage of an exemption in the name of the Rupee Payment Mechanism, where settlement is in Indian rupees through specific Indian banks such as the UCO Bank. Settlement is credited to Iranian banks' Vostro accounts. It is a payment mechanism employed to enable trade of critical products such as medicine without breaching sanction.
Apart from this, some of these organizations also engage in barter exchange -- trading Indian commodities (such as rice or tea) with Iranian medicines. For pricier exchanges, euro-based transactions through third parties are also possible. Whatever the medium, it is all about secure, transparent transactions in order to obey both the Iranian and Indian governments.

Conclusion

The potential of widened Iranian exports of medicines is a clear-eyed vision of the pharmaceutical future. To India, presenting the twin challenge of offering cheap medicine and serving its billion-member populace, medicines from Iran are a balancing act of affordability and quality. Iranian biosimilars, generics, APIs, and herbal medicines can emerge as an ideal addition to India's current imports from Europe, America, and China.
The procedure needs to be carried out judiciously, though. The importers will need to receive appropriate clearances from CDSCO, abide by India's quality norms, and possess efficient logistics chains. Transactions will also need to occur in permitted-friendly options like the rupee mechanism. But with everything, the benefits are enormous: savings in purchase amounts, improved choice of medicines, and potential collaborative cooperation in R&D and technology transfer.
As India solidifies its position as a global pharma leader, joint ventures with Iran can bring depth and diversification to its pharma supply chain. In the future, greater Iran pharma trade cooperation not only can be lucrative but will be a direct advantage to Indian patients through access to low-cost medicines.